Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors

Alfonso Martin-Fontecha, Federica Cavallo, Matteo Bellone, Silvia Heltai, Giandomenica Lezzi, Paola Tornaghi, Nasrin Nabavi, Guido Forni, Paolo Dellabona, Giulia Casorati

Research output: Contribution to journalArticle

Abstract

Experimental mouse tumors are classified as intrinsically immunogenic when, after a single injection into syngeneic mice as nonreplicating cell vaccines, they elicit a protective immune response against a subsequent lethal challenge. Tumors that do not retain this residual immunogenicity are defined as poorly immunogenic or nonimmunogenic. The expression of the B7-1 co-stimulatory molecule on immunogenic tumors can further increase their capacity to induce a T cell-dependent anti-tumor immunity, whereas it has limited effects on nonimmunogenic tumors. Recently, B7-2, a second molecule with an apparently similar co-stimulatory activity, has been cloned. In this report, we compare the efficiency of nonreplicating cells from one immunogenic and two nonimmunogenic mouse tumors transfected with B7-1 or B7-2 in the induction of protective and curative anti-tumor immunity. Immunogenic lymphoma cells expressing B7-1 or B7-2 are equally effective in both protecting against a subsequent challenge and curing established tumors. By contrast, nonimmunogenic adenocarcinoma and melanoma cells expressing B7-2 provide superior protective immunity, and only B7-2+ adenocarcinoma cells induce an efficient curative immunity. CD8+ and polymorphonuclear cells, but not CD4+ T cells, are critically involved in the rejection of the adenocarcinoma elicited by both B7-1+ and B7-2+ vaccines. These data indicate that B7-1 and B7-2 are not redundant co-stimulatory molecules and that, in these experimental models, B7-2 is superior to B7-1 in the induction of an efficient immunity when the immunogenicity of a tumor is a limiting factor.

Original languageEnglish
Pages (from-to)1851-1859
Number of pages9
JournalEuropean Journal of Immunology
Volume26
Issue number8
Publication statusPublished - 1996

Fingerprint

Immunity
Neoplasms
Adenocarcinoma
Therapeutics
Vaccines
T-Lymphocytes
Melanoma
Lymphoma
Theoretical Models
Injections

Keywords

  • Anti-tumor immunity
  • B7-1
  • B7-2
  • Co-stimulation
  • Tumor immunogenicity

ASJC Scopus subject areas

  • Immunology

Cite this

Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors. / Martin-Fontecha, Alfonso; Cavallo, Federica; Bellone, Matteo; Heltai, Silvia; Lezzi, Giandomenica; Tornaghi, Paola; Nabavi, Nasrin; Forni, Guido; Dellabona, Paolo; Casorati, Giulia.

In: European Journal of Immunology, Vol. 26, No. 8, 1996, p. 1851-1859.

Research output: Contribution to journalArticle

Martin-Fontecha, Alfonso ; Cavallo, Federica ; Bellone, Matteo ; Heltai, Silvia ; Lezzi, Giandomenica ; Tornaghi, Paola ; Nabavi, Nasrin ; Forni, Guido ; Dellabona, Paolo ; Casorati, Giulia. / Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors. In: European Journal of Immunology. 1996 ; Vol. 26, No. 8. pp. 1851-1859.
@article{8fa8ac1e3c4744999a22ef6fd9e28bff,
title = "Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors",
abstract = "Experimental mouse tumors are classified as intrinsically immunogenic when, after a single injection into syngeneic mice as nonreplicating cell vaccines, they elicit a protective immune response against a subsequent lethal challenge. Tumors that do not retain this residual immunogenicity are defined as poorly immunogenic or nonimmunogenic. The expression of the B7-1 co-stimulatory molecule on immunogenic tumors can further increase their capacity to induce a T cell-dependent anti-tumor immunity, whereas it has limited effects on nonimmunogenic tumors. Recently, B7-2, a second molecule with an apparently similar co-stimulatory activity, has been cloned. In this report, we compare the efficiency of nonreplicating cells from one immunogenic and two nonimmunogenic mouse tumors transfected with B7-1 or B7-2 in the induction of protective and curative anti-tumor immunity. Immunogenic lymphoma cells expressing B7-1 or B7-2 are equally effective in both protecting against a subsequent challenge and curing established tumors. By contrast, nonimmunogenic adenocarcinoma and melanoma cells expressing B7-2 provide superior protective immunity, and only B7-2+ adenocarcinoma cells induce an efficient curative immunity. CD8+ and polymorphonuclear cells, but not CD4+ T cells, are critically involved in the rejection of the adenocarcinoma elicited by both B7-1+ and B7-2+ vaccines. These data indicate that B7-1 and B7-2 are not redundant co-stimulatory molecules and that, in these experimental models, B7-2 is superior to B7-1 in the induction of an efficient immunity when the immunogenicity of a tumor is a limiting factor.",
keywords = "Anti-tumor immunity, B7-1, B7-2, Co-stimulation, Tumor immunogenicity",
author = "Alfonso Martin-Fontecha and Federica Cavallo and Matteo Bellone and Silvia Heltai and Giandomenica Lezzi and Paola Tornaghi and Nasrin Nabavi and Guido Forni and Paolo Dellabona and Giulia Casorati",
year = "1996",
language = "English",
volume = "26",
pages = "1851--1859",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "8",

}

TY - JOUR

T1 - Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors

AU - Martin-Fontecha, Alfonso

AU - Cavallo, Federica

AU - Bellone, Matteo

AU - Heltai, Silvia

AU - Lezzi, Giandomenica

AU - Tornaghi, Paola

AU - Nabavi, Nasrin

AU - Forni, Guido

AU - Dellabona, Paolo

AU - Casorati, Giulia

PY - 1996

Y1 - 1996

N2 - Experimental mouse tumors are classified as intrinsically immunogenic when, after a single injection into syngeneic mice as nonreplicating cell vaccines, they elicit a protective immune response against a subsequent lethal challenge. Tumors that do not retain this residual immunogenicity are defined as poorly immunogenic or nonimmunogenic. The expression of the B7-1 co-stimulatory molecule on immunogenic tumors can further increase their capacity to induce a T cell-dependent anti-tumor immunity, whereas it has limited effects on nonimmunogenic tumors. Recently, B7-2, a second molecule with an apparently similar co-stimulatory activity, has been cloned. In this report, we compare the efficiency of nonreplicating cells from one immunogenic and two nonimmunogenic mouse tumors transfected with B7-1 or B7-2 in the induction of protective and curative anti-tumor immunity. Immunogenic lymphoma cells expressing B7-1 or B7-2 are equally effective in both protecting against a subsequent challenge and curing established tumors. By contrast, nonimmunogenic adenocarcinoma and melanoma cells expressing B7-2 provide superior protective immunity, and only B7-2+ adenocarcinoma cells induce an efficient curative immunity. CD8+ and polymorphonuclear cells, but not CD4+ T cells, are critically involved in the rejection of the adenocarcinoma elicited by both B7-1+ and B7-2+ vaccines. These data indicate that B7-1 and B7-2 are not redundant co-stimulatory molecules and that, in these experimental models, B7-2 is superior to B7-1 in the induction of an efficient immunity when the immunogenicity of a tumor is a limiting factor.

AB - Experimental mouse tumors are classified as intrinsically immunogenic when, after a single injection into syngeneic mice as nonreplicating cell vaccines, they elicit a protective immune response against a subsequent lethal challenge. Tumors that do not retain this residual immunogenicity are defined as poorly immunogenic or nonimmunogenic. The expression of the B7-1 co-stimulatory molecule on immunogenic tumors can further increase their capacity to induce a T cell-dependent anti-tumor immunity, whereas it has limited effects on nonimmunogenic tumors. Recently, B7-2, a second molecule with an apparently similar co-stimulatory activity, has been cloned. In this report, we compare the efficiency of nonreplicating cells from one immunogenic and two nonimmunogenic mouse tumors transfected with B7-1 or B7-2 in the induction of protective and curative anti-tumor immunity. Immunogenic lymphoma cells expressing B7-1 or B7-2 are equally effective in both protecting against a subsequent challenge and curing established tumors. By contrast, nonimmunogenic adenocarcinoma and melanoma cells expressing B7-2 provide superior protective immunity, and only B7-2+ adenocarcinoma cells induce an efficient curative immunity. CD8+ and polymorphonuclear cells, but not CD4+ T cells, are critically involved in the rejection of the adenocarcinoma elicited by both B7-1+ and B7-2+ vaccines. These data indicate that B7-1 and B7-2 are not redundant co-stimulatory molecules and that, in these experimental models, B7-2 is superior to B7-1 in the induction of an efficient immunity when the immunogenicity of a tumor is a limiting factor.

KW - Anti-tumor immunity

KW - B7-1

KW - B7-2

KW - Co-stimulation

KW - Tumor immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=9444225462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444225462&partnerID=8YFLogxK

M3 - Article

C2 - 8765031

AN - SCOPUS:9444225462

VL - 26

SP - 1851

EP - 1859

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 8

ER -